



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450
ON: April 6, 2005

Maryam D. Sattar
ATTORNEY FOR APPLICANT

April 6, 2005
DATE

Attorney Docket No. P31220X2C2-R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Leonard, et al. 06 April 2005
Serial No.: 10/024,858 Group Art Unit No.: 1615
Filed: December 18, 2001 Examiner: Humera Sheikh
For: "PAROXETINE CONTROLLED RELEASE COMPOSITIONS"

Commissioner for Patents
BOX RCE
P.O. Box 1450
Alexandria, VA 22313-1450

FILING OF AN INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97(b) AND 37 C.F.R. §1.114(c)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except for those documents which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.


This application was allowed at the time of filing an RCE concurrent with this IDS. A review of documents cited during the prosecution of foreign applications corresponding to the subject United States application was conducted. This Information Disclosure Statement contains the documents, including an opposition statement, cited during the prosecution of foreign applications that correspond to the subject United States application that are not already part of the filewrapper. In citing these documents applicants note the following.

Serial No.: 10/024,858
Group Art Unit No.: 1615

- i). JP A 1-311024 corresponds to EP 0338444 (German). These documents are submitted herein in the form of corresponding United States Patent No. 5,271,946 (Hettche).
- ii). HU P9601665A is submitted herein in the form of corresponding International Publication No. WO 95/16448.
- iii). JP A 11-503163 is submitted herein in the form of corresponding International Publication No. WO 96/31197.
- iv). JP A 10-508597 is submitted herein in the form of corresponding International Publication No. WO 96/14059.
- v). HU P9601991 is submitted herein in the form of corresponding International Publication No. WO 95/19956.

This Information Disclosure Statement is intended to notify the United States Patent and Trademark Office to the existence of the documents cited during the prosecution of foreign applications that correspond to the subject United States application. Applicants contend that the currently pending claims are allowable over the enclosed documents.

Respectfully submitted,


Wayne J. Dustman
Attorney for Applicants
Registration No. 33,870

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5023
Facsimile (610) 270-5090

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P31220X2C2R2SERIAL NO.
10/024,858INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

APR 12 2005 (Use several sheets if necessary)

APPLICANT

Leonard, et al.

FILING DATE

December 18, 2001

GROUP

1625

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	3,536,809	10/27/1970	Appleweig			
	3,598,123	08/10/1971	Zaffaroni			
	3,630,200	12/28/1971	Higuchi			
	3,845,770	11/05/1974	Theeuwes, et al.			
	3,916,899	11/04/1975	Theeuwes, et al.			
	4,007,196	02/08/1977	Christensen, et al.			
	4,008,719	02/22/1977	Theeuwes, et al.			
	4,085,225	04/18/1978	Welle, et al.			
	4,314,081	02/02/1982	Molloy, et al.			
	4,444,778	04/24/1984	Coughlin			
	4,536,518	08/20/1985	Welch, Jr., et al.			
	4,615,697	10/07/1986	Robinson			
	4,721,723	01/26/1988	Barnes, et al.			
	4,797,286	01/10/1989	Thakkar, et al.			
	4,996,358	02/26/1991	Handa, et al.			
	4,988,679	01/29/1991	Chavkin, et al.			
	5,110,605	05/05/1992	Acharya			
	5,271,946	12/21/1993	Hettche			
	5,371,092	12/06/1994	Johnson			
	5,686,094	11/11/1997	Acharya			
	6,133,289	10/17/2000	Ward, et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No
	WO 95/16448	22.06.95	WIPO				
	WO 96/31197	10.10.96	WIPO				
	WO 96/14059	17.05.96	WIPO				
	WO 97/02037	23.01.97	WIPO				
	WO 95/19956	27.07.95	WIPO				
	WO 92/13452	20.08.92	WIPO				
	WO 93/09769	27.05.93	WIPO				

Form PTO-1449

U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
P31220X2C2R2SERIAL NO.
10/024,858INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

APPLICANT
Leonard, et al.FILING DATE
December 18, 2001GROUP
1625

FOREIGN PATENT DOCUMENTS

	WO 95/30422	16.11.95	WIPO				
	WO 97/43249	20.11.97	WIPO				
	WO 97/03966	06.02.97	WIPO				
	WO 97/26257	24.07.97	WIPO				
	WO 96/33166	24.10.96	WIPO				
	WO 97/02239	23.01.97	WIPO				
	WO 96/02240	01.02.96	WIPO				
	WO 98/43959	08.10.98	WIPO				
	WO 94/10990	26.05.94	WIPO				
	WO 96/33165	24.10.96	WIPO				
	0 449 562 A2	26.03.91	EP				
	2 143 070	2001/12/18	Canada				
	2 031 393	1989/12/14	Canada				
	1 298 479	1992/04/07	Canada				
	5 139 964	1993/06/08	Japan (translation)				
	4 036 237	1992/02/06	Japan (translation)				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Chambers Science and Technology Dictionary, 1994.
	Duboff, J. Clin. Psychopharmacology, 1993, Vol. 13, No. 6, pp. 28S-33S.
	Conte, et al., Travaux Originaux Research Papers, September 1993.
	Conte, et al., J. of Controlled Release, 1993, Vol. 26, pp. 39-47.
	Harten, et al., Clin. Pharmacokinet, 1993, Vol. 24, No. 2, pp. 177-182.
	Bergeron, et al., Am. J. Psychiatry, 1994, Vol. 151, No. 7, pp. 1084-1086.
	Dunner, et al., J. Clin. Psychiatry, 1992, Vol. 53, No. 2, pp. 21-22.
	Golden, Psychopharmacology Bulletin, 2003, Vol. 37, Supp. 1, pp. 176-186.
	Turkish Application No. TR99/317, Examination Report (translation) 1980.
	Opposition to Israeli Appl. No. 122940, Unipharm LTD v. SmithKline Beecham, Jan. 2002
	Remington's Pharma Sciences, Editorial Panamerica Co., 1980 (17 th edition) - (translation)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.